Better Health Requires More Participation by Young People
At this year’s World Health Summit in Berlin, the WHO Youth Council presented its vision for healthier societies. The World Health Organization’s Youth Council is calling on policymakers to better leverage the potential of young people. The Bertelsmann Stiftung and major youth organizations support the initiative.
Berlin/Gütersloh, October 14, 2024 – Better involvement of and support for young people is essential to creating a healthier, more equitable, and future-proof society. That is the key message of a declaration published by the World Health Organization’s 25-member WHO Youth Council supported by the Bertelsmann Stiftung at the World Health Summit in Berlin. The authors of the declaration emphasized that especially younger generations are severely affected by the global crises. The WHO had only recently pointed out that numerous diseases are on the rise among young people worldwide, especially mental and sexual illnesses. In the search for solutions, it is important not only to listen to young people, but also to entrust them with an active role and responsibility.
Specifically, the WHO Youth Council is calling for more equal opportunity and inclusion in the education system and in the use of new technologies, e.g. Furthermore, healthcare should be geared more towards prevention, and people from disadvantaged groups should be guaranteed equal access to healthcare services. The authors of the declaration also call for better support for youth organizations and for empowering young people to help shape (healthcare) policy, both through new formats for participation and by being genuinely open to their positions and experiences. Besides the Bertelsmann Stiftung, international youth organizations support the declaration, including the Digital Transformations for Health Lab and the Junior Doctors Network of the World Medical Association.
“Young people make up around a third of the world’s population, but are insufficiently involved in political decision-making processes,” noted Bertelsmann Stiftung Executive Board Chairman Ralph Heck. “This is a problem because will be affected by the consequences of today’s political decisions for a long time. If their positions are not heard, opinion-forming will be imbalanced. A strong democracy needs the voice of young people.”
Brigitte Mohn, Executive Director of the Bertelsmann Stiftung, emphasized: “Health has many facets and is highly relevant to the further development and transformation of societies on all continents. We need the perspectives of young people here. They must necessarily be involved in all decisions, for example in the transition to a digital and sustainable economy, the structuring of social life in the digital age, and the development of new ways to ensure global access to education and natural resources. They are the ones who must help shape the future of their countries and take responsibility for it at a later date.”
Daniela Schwarzer, Executive Director of the Bertelsmann Stiftung, added: “In healthcare as in other sectors, the major challenges can only be solved at an international level and through close cooperation. The measures described by the WHO Youth Council provide a good starting point. However, their implementation depends crucially on whether it is possible to incorporate these calls for action into the political process. This is where political decision-makers are called upon to seriously consider the proposals of our young health experts.”
Contacts
Our expert:
Malte Etienne, Phone: +49 (0) 30 27 57 88 325
Email: malte.etienne@bst-gesundheit.de
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
INTERSPORT Austria acquires INTERSPORT Slovenia Group15.1.2026 15:16:10 CET | Press release
Strategic move strengthens market position in Central Europe, with over 500 locations in 12 countries and more than € 1 billion in sales
VORN Bioenergy announces appointments to leadership team15.1.2026 11:14:45 CET | Press release
Regensburg. VORN Bioenergy today announces the appointment of Jörg Lennertz as Chief Executive Officer and Manuel Fernández Durán as Chief Financial Officer. Jörg and Manuel together with Michael Wallis Olausson form the new management team.
Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 13:42:00 CET | Press release
Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions
ORTEC expands German healthcare footprint with strategic acquisition of Klages & Partner13.1.2026 09:00:00 CET | Press release
Acquisition adds over 200 healthcare customers and sector-specific workforce management expertise to ORTEC’s portfolio
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom